 purg breast cancer mononuclear cell fraction bone marrow patient high-dos chemotherapi autolog marrow support phase trial ex vivo bone marrow treatment breast cancer patient high-dos chemotherapi autolog bone marrow support abm activ deriv cyclophosphamid known activ breast cancer phase marrow trial ficoll-separ mononuclear cell mnc devoid granulocyt rbc buffi coat twenty-f patient metastat breast cancer patient cycl adriamycin doxorubicin adria columbu OH fluorouracil methotrex duke afm regimen marrow harvest mnc fraction marrow concentr micrograms/ml patient micrograms/ml patient micrograms/ml patient micrograms/ml patient patient high-dos system cyclophosphamid cisplatin carmustin infus purg marrow studi end point marrow engraft wbc count cell microlit first dose level micrograms/ml signific delay time day unpurg histor control day micrograms/ml engraft concentr escal signific correl time leukocyt engraft concentr methylcellulose-bas tissu cultur assay signific correl colony-form unit-granulocyte-macrophag cfu-gm content purg marrow day ninety-f percent patient entir program follow-up ultim benefit intens therapi long-term surviv